Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00203463 · ClinicalTrials.gov registry record · Phase 4

Topiramate in the Treatment of Post Traumatic Stress Disorder (PTSD)

A Phase 4 study of PTSD, sponsored by Tuscaloosa Research & Education Advancement Corporation.

Completed
Registry status
Phase 4
Development phase
40
Enrollment target
1
Study location

NCT00203463: Completed Phase 4 study of PTSD, sponsored by Tuscaloosa Research & Education Advancement Corporation.

NCT00203463 is a Phase 4 study of PTSD that has completed, run by Tuscaloosa Research & Education Advancement Corporation. The registered enrollment target is 40 participants, below the 302-participant average among 154 other PTSD trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00203463, a Phase 4 study of PTSD, has completed, sponsored by Tuscaloosa Research & Education Advancement Corporation.

COMPLETED
Registry status
Phase 4
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

To study the potential therapeutic effects of topiramate (Topamax) in the treatment of PTSD.

Conditions Studied

Interventions

  • DRUG topiramate

Study Locations (1)

Alabama

  • Tuscaloosa Research & Education Advancement Corporation - Tuscaloosa

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2001-07
Est. Completion 2004-09
Phase Phase 4

What the finished NCT00203463 record still lists

NCT00203463 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 302-participant average among 154 other PTSD trials with a reported enrollment target (87% lower).

The record links to 1 condition, with PTSD appearing as the primary indexed condition, and to 1 intervention - of which topiramate is the first listed.

NCT00203463 reports a single indexed study location in Alabama.

Frequently Asked Questions

What is clinical trial NCT00203463 about?

NCT00203463 is a clinical study titled "Topiramate in the Treatment of Post Traumatic Stress Disorder (PTSD)". To study the potential therapeutic effects of topiramate (Topamax) in the treatment of PTSD.

What is the current status of trial NCT00203463?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2001-07. Estimated completion is 2004-09.

What conditions does trial NCT00203463 study?

This clinical trial studies the following conditions: PTSD.

What interventions are being tested in trial NCT00203463?

The interventions under investigation include: topiramate (DRUG).

Who is sponsoring clinical trial NCT00203463?

This trial is sponsored by Tuscaloosa Research & Education Advancement Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00203463 being conducted?

This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for PTSD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00203463's enrollment target sits among peer trials

40 106th of 154 higher than 41 of 154 other PTSD trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other PTSD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00203463, the US trial registry maintained by the National Library of Medicine. NCT00203463 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.